Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloproliferative disorders.

Jerry L Spivak1, Giovanni Barosi, Gianni Tognoni

  • 1Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD 21205-2109, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The end of life as a test of a culture of care].

Assistenza infermieristica e ricerca : AIR·2025
Same author

[Care on the move. The power of the therapeutic alliance].

Assistenza infermieristica e ricerca : AIR·2025
Same author

[Mandatory memories for 2025, and far beyond].

Assistenza infermieristica e ricerca : AIR·2025
Same author

[Is it possible, does it make sense, or is it mandatory, to think 'about the future' in very confused times?]

Assistenza infermieristica e ricerca : AIR·2024
Same author

[Is it possible, or even mandatory, to confront the unspeakable?]

Assistenza infermieristica e ricerca : AIR·2024
Same author

[The controversial political plan of 'differentiation' of the regional autonomy].

Assistenza infermieristica e ricerca : AIR·2024
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Diagnosis and management of Philadelphia chromosome-negative chronic myeloproliferative disorders (CMPD) like polycythemia vera (PV) and essential thrombocythemia (ET) are challenging. New molecular assays and risk-stratified treatments, including aspirin for PV, show promise.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Background:

  • Chronic myeloproliferative disorders (CMPD), including polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF), present overlapping clinical features, complicating diagnosis and management.
  • Lack of specific diagnostic markers and understanding of molecular underpinnings hinder effective treatment strategies for these conditions.

Purpose of the Study:

  • To review current diagnostic challenges and molecular assays for CMPD.
  • To evaluate evidence-based treatment strategies for PV and ET.
  • To discuss the role of aspirin in PV and novel therapies for IMF.

Main Methods:

  • Review of clinical controversies and diagnostic challenges in CMPD.
  • Analysis of molecular assays, including PRV-1 mRNA and Mpl expression.

Related Experiment Videos

  • Evaluation of treatment strategies for PV and ET, including phlebotomy, cytoreductive therapy, and risk stratification.
  • Assessment of aspirin efficacy in PV via the ECLAP study.
  • Review of IMF pathophysiology and emerging therapies like thalidomide and stem cell transplantation.

    • Main Results:

    • Overexpression of PRV-1 mRNA may aid PV diagnosis, while Mpl expression abnormalities are observed across PV, ET, and IMF.
    • Phlebotomy remains a cornerstone for PV treatment; cytoreductive therapy requires risk stratification in ET.
    • Low-dose aspirin in PV reduced cardiovascular events and mortality with a slight, non-significant increase in bleeding.
    • Thalidomide showed response rates of 31% in IMF, particularly benefiting anemia, thrombocytopenia, and splenomegaly.

    Conclusions:

    • Molecular assays like PRV-1 and Mpl assessment offer potential diagnostic insights for CMPD.
    • Risk-adapted treatment strategies, including phlebotomy for PV and cautious use of cytoreductive agents for ET, are crucial.
    • Aspirin therapy is beneficial for cardiovascular risk reduction in PV.
    • Emerging therapies like thalidomide demonstrate potential in managing IMF symptoms.